Clear Search

Showing 2 result for “KEEPsAKE 1”.

November 2022

活動性乾癬性関節炎に対するrisankizumab の有効性と安全性: KEEPsAKE 1 試験の52週結果

Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keac607

Risankizumab (RZB) improves the signs and symptoms of PsA, with efficacy maintained through 52 weeks. Alongside the efficacy data, this analysis of KEEPsAKE 1 also evaluates the safety and tolerability profile of RZB.


August 2022

Risankizumab は乾癬性関節炎の健康関連の生活の質, 疼痛, 労働生産性を改善: KEEPsAKE 1

Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keac342

In this study risankizumab treatment resulted in greater improvements in fatigue and pain than placebo. Prior to this finding the study aimed to evaluate the impact of risankizumab on HRQoL and other PROs among patients with active PsA and inadequate response or intolerance to csDMARD-IR in the KEEPsAKE 1 trial.